FTSE All-Share
|
4 303,84
|
23,95
|
0,56%
|
Analysen zu FTSE All-Share-Werten
| 06.02.25 | Rio Tinto Neutral | UBS AG | |
| 06.02.25 | GSK Neutral | UBS AG | |
| 05.02.25 | GSK Neutral | Goldman Sachs Group Inc. | |
| 05.02.25 | Diageo Outperform | Bernstein Research | |
| 05.02.25 | Diageo Sell | Deutsche Bank AG | |
| 05.02.25 | GSK Outperform | Bernstein Research | |
| 05.02.25 | GSK Neutral | UBS AG | |
| 05.02.25 | BAT Neutral | Goldman Sachs Group Inc. | |
| 05.02.25 | Diageo Sell | Goldman Sachs Group Inc. | |
| 05.02.25 | Diageo Buy | UBS AG | |
| 05.02.25 | Vodafone Group Neutral | JP Morgan Chase & Co. | |
| 05.02.25 | Vodafone Group Neutral | JP Morgan Chase & Co. | |
| 05.02.25 | GSK Underweight | JP Morgan Chase & Co. | |
| 05.02.25 | Unilever Outperform | Bernstein Research | |
| 05.02.25 | London Stock Exchange Overweight | JP Morgan Chase & Co. | |
| 04.02.25 | Vodafone Group Buy | Deutsche Bank AG | |
| 04.02.25 | Diageo Sector Perform | RBC Capital Markets | |
| 04.02.25 | Diageo Neutral | JP Morgan Chase & Co. | |
| 04.02.25 | Diageo Buy | UBS AG | |
| 04.02.25 | Vodafone Group Neutral | UBS AG | |
| 04.02.25 | Diageo Sell | Goldman Sachs Group Inc. | |
| 04.02.25 | Vodafone Group Neutral | Goldman Sachs Group Inc. | |
| 03.02.25 | Diageo Neutral | JP Morgan Chase & Co. | |
| 03.02.25 | Diageo Buy | Jefferies & Company Inc. | |
| 03.02.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 03.02.25 | HSBC Holdings Sector Perform | RBC Capital Markets | |
| 03.02.25 | Unilever Sell | UBS AG | |
| 03.02.25 | HSBC Holdings Buy | Goldman Sachs Group Inc. | |
| 03.02.25 | HSBC Holdings Hold | Deutsche Bank AG | |
| 31.01.25 | Shell Outperform | RBC Capital Markets | |
| 31.01.25 | Shell Buy | UBS AG | |
| 30.01.25 | Shell Overweight | JP Morgan Chase & Co. | |
| 30.01.25 | Shell Buy | Jefferies & Company Inc. | |
| 30.01.25 | Shell Outperform | RBC Capital Markets | |
| 30.01.25 | GSK Underweight | JP Morgan Chase & Co. | |
| 30.01.25 | Diageo Neutral | JP Morgan Chase & Co. | |
| 30.01.25 | GSK Neutral | UBS AG | |
| 30.01.25 | AstraZeneca Neutral | UBS AG | |
| 30.01.25 | Shell Outperform | RBC Capital Markets | |
| 30.01.25 | Shell Buy | UBS AG |
Analysen zu Aktien folgender Indizes
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.